Jazz Pharmaceuticals plc (JAZZ) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
60/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinJAZZ / S&P 27.46% / 15.20% |
LoseJAZZ / S&P 12.59% / 15.00% |
LoseJAZZ / S&P -314.52% / 50.40% |
| 2026-Q11/3 |
WinJAZZ / S&P 11.21% / -4.33% |
LoseJAZZ / S&P 9.20% / 11.30% |
LoseJAZZ / S&P -98.52% / 27.70% |
| 2025-Q41/3 |
WinJAZZ / S&P 28.98% / 2.65% |
LoseJAZZ / S&P 4.88% / 9.00% |
LoseJAZZ / S&P -167.13% / 13.40% |
| 2025-Q31/3 |
WinJAZZ / S&P 24.20% / 8.12% |
LoseJAZZ / S&P 4.13% / 4.61% |
LoseJAZZ / S&P -186.64% / 13.45% |
| 2025-Q20/3 |
LoseJAZZ / S&P -14.52% / 10.94% |
LoseJAZZ / S&P 4.52% / 4.83% |
LoseJAZZ / S&P -216.98% / 10.63% |
| 2025-Q13/3 |
WinJAZZ / S&P 0.81% / -4.27% |
WinJAZZ / S&P 5.76% / 4.98% |
WinJAZZ / S&P 52.47% / 10.57% |
| 2024-Q43/3 |
WinJAZZ / S&P 10.54% / 2.41% |
WinJAZZ / S&P 6.12% / 5.25% |
WinJAZZ / S&P 41.92% / 6.15% |
| 2024-Q31/3 |
LoseJAZZ / S&P 4.38% / 5.89% |
LoseJAZZ / S&P 5.23% / 5.89% |
WinJAZZ / S&P 726.74% / 6.11% |
| 2024-Q20/3 |
LoseJAZZ / S&P -11.37% / 4.28% |
LoseJAZZ / S&P 3.91% / 5.38% |
LoseJAZZ / S&P -466.67% / 5.12% |
| 2024-Q10/3 |
LoseJAZZ / S&P -2.10% / 10.56% |
LoseJAZZ / S&P 2.81% / 5.71% |
LoseJAZZ / S&P -289.84% / 5.59% |
| 2023-Q40/3 |
LoseJAZZ / S&P -4.98% / 11.69% |
LoseJAZZ / S&P 4.78% / 6.81% |
LoseJAZZ / S&P -271.71% / 7.78% |
| 2023-Q31/3 |
WinJAZZ / S&P 4.41% / -3.27% |
LoseJAZZ / S&P 5.87% / 7.52% |
LoseJAZZ / S&P -418.52% / -5.03% |
| 2023-Q21/3 |
LoseJAZZ / S&P -15.28% / 8.74% |
LoseJAZZ / S&P 8.08% / 9.50% |
WinJAZZ / S&P 93.90% / -8.57% |
| 2023-Q11/3 |
LoseJAZZ / S&P -8.15% / 7.50% |
WinJAZZ / S&P 13.27% / 10.77% |
LoseJAZZ / S&P -65.78% / -15.69% |
| 2022-Q42/3 |
WinJAZZ / S&P 19.52% / 7.56% |
WinJAZZ / S&P 18.26% / 11.88% |
LoseJAZZ / S&P -34.13% / -17.99% |
| 2022-Q31/3 |
LoseJAZZ / S&P -14.56% / -4.88% |
WinJAZZ / S&P 25.18% / 13.47% |
LoseJAZZ / S&P -89.33% / -1.41% |
| 2022-Q22/3 |
WinJAZZ / S&P 0.22% / -16.10% |
WinJAZZ / S&P 32.59% / 13.71% |
LoseJAZZ / S&P -184.54% / 11.04% |
| 2022-Q12/3 |
WinJAZZ / S&P 22.19% / -4.60% |
WinJAZZ / S&P 35.46% / 15.97% |
LoseJAZZ / S&P -181.84% / 42.23% |
| 2021-Q41/3 |
LoseJAZZ / S&P -2.16% / 11.03% |
WinJAZZ / S&P 30.91% / 15.00% |
LoseJAZZ / S&P -228.13% / 96.40% |
| 2021-Q31/3 |
LoseJAZZ / S&P -26.70% / 0.58% |
WinJAZZ / S&P 25.58% / 10.77% |
LoseJAZZ / S&P -179.81% / 69.42% |
| 2021-Q21/3 |
LoseJAZZ / S&P 8.07% / 8.55% |
WinJAZZ / S&P 18.46% / 6.58% |
LoseJAZZ / S&P -58.01% / 51.81% |
| 2021-Q12/3 |
LoseJAZZ / S&P -0.41% / 6.17% |
WinJAZZ / S&P 11.34% / -1.06% |
WinJAZZ / S&P 90.02% / 7.39% |
| 2020-Q42/3 |
WinJAZZ / S&P 15.75% / 12.15% |
WinJAZZ / S&P 9.34% / -3.72% |
LoseJAZZ / S&P -53.52% / -33.42% |
| 2020-Q32/3 |
WinJAZZ / S&P 29.23% / 8.93% |
WinJAZZ / S&P 10.86% / -2.04% |
LoseJAZZ / S&P -69.61% / -27.10% |
| 2020-Q21/3 |
LoseJAZZ / S&P 10.63% / 20.54% |
WinJAZZ / S&P 11.49% / -0.46% |
LoseJAZZ / S&P -79.11% / -27.11% |
| 2020-Q11/3 |
LoseJAZZ / S&P -33.19% / -19.60% |
WinJAZZ / S&P 11.96% / 3.47% |
LoseJAZZ / S&P -39.87% / -14.75% |
| 2019-Q43/3 |
WinJAZZ / S&P 16.50% / 9.07% |
WinJAZZ / S&P 14.32% / 5.36% |
WinJAZZ / S&P 25.00% / 2.99% |
| 2019-Q32/3 |
LoseJAZZ / S&P -10.12% / 1.70% |
WinJAZZ / S&P 11.11% / 5.02% |
WinJAZZ / S&P 23.43% / 0.21% |
| 2019-Q22/3 |
LoseJAZZ / S&P -0.27% / 4.30% |
WinJAZZ / S&P 10.86% / 6.64% |
WinJAZZ / S&P 56.44% / 8.65% |
| 2019-Q12/3 |
WinJAZZ / S&P 15.32% / 13.65% |
WinJAZZ / S&P 15.84% / 8.12% |
LoseJAZZ / S&P 9.74% / 14.29% |
| 2018-Q41/3 |
LoseJAZZ / S&P -26.27% / -13.52% |
WinJAZZ / S&P 16.82% / 9.05% |
LoseJAZZ / S&P -8.43% / 18.23% |
| 2018-Q32/3 |
LoseJAZZ / S&P -2.42% / 7.71% |
WinJAZZ / S&P 17.22% / 10.21% |
WinJAZZ / S&P 39.44% / 19.06% |
| 2018-Q22/3 |
WinJAZZ / S&P 14.11% / 3.43% |
WinJAZZ / S&P 16.36% / 9.03% |
LoseJAZZ / S&P 9.10% / 14.46% |
| 2018-Q12/3 |
WinJAZZ / S&P 12.14% / -0.76% |
WinJAZZ / S&P 10.42% / 7.68% |
LoseJAZZ / S&P 10.29% / 12.46% |
| 2017-Q42/3 |
LoseJAZZ / S&P -7.93% / 6.64% |
WinJAZZ / S&P 8.79% / 7.03% |
WinJAZZ / S&P 24.02% / 13.82% |
| 2017-Q31/3 |
LoseJAZZ / S&P -5.95% / 4.48% |
WinJAZZ / S&P 10.24% / 5.68% |
LoseJAZZ / S&P 3.95% / 17.57% |
| 2017-Q22/3 |
WinJAZZ / S&P 7.15% / 3.09% |
WinJAZZ / S&P 10.17% / 4.83% |
LoseJAZZ / S&P 12.31% / 17.74% |
| 2017-Q13/3 |
WinJAZZ / S&P 33.11% / 6.07% |
WinJAZZ / S&P 13.06% / 3.67% |
WinJAZZ / S&P 24.25% / 13.32% |
| 2016-Q42/3 |
LoseJAZZ / S&P -10.25% / 3.82% |
WinJAZZ / S&P 12.32% / 2.09% |
WinJAZZ / S&P 22.56% / 7.05% |
| 2016-Q32/3 |
LoseJAZZ / S&P -14.03% / 3.85% |
WinJAZZ / S&P 9.16% / 0.20% |
WinJAZZ / S&P 11.47% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | JAZZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 96.56% | 20.78% |
| Annualized return | 96.56% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | JAZZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 90.27% | 83.14% |
| Annualized return | 13.73% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | JAZZ total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 103.63% | 319.30% |
| Annualized return | 7.37% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |